EA202090875A1 - METHODS FOR TREATMENT OF HEART FAILURE WITH REDUCED EMISSION FRACTION WITH DAPAGLIFLOSIN - Google Patents

METHODS FOR TREATMENT OF HEART FAILURE WITH REDUCED EMISSION FRACTION WITH DAPAGLIFLOSIN

Info

Publication number
EA202090875A1
EA202090875A1 EA202090875A EA202090875A EA202090875A1 EA 202090875 A1 EA202090875 A1 EA 202090875A1 EA 202090875 A EA202090875 A EA 202090875A EA 202090875 A EA202090875 A EA 202090875A EA 202090875 A1 EA202090875 A1 EA 202090875A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heart failure
methods
dapagliflosin
treatment
reduced emission
Prior art date
Application number
EA202090875A
Other languages
Russian (ru)
Inventor
Анна Мария Лангкилде
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Priority claimed from PCT/EP2020/056211 external-priority patent/WO2021037400A1/en
Publication of EA202090875A1 publication Critical patent/EA202090875A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Настоящее изобретение относится к способам лечения пациентов с сердечной недостаточностью со сниженной фракцией выброса (HFrEF), с диабетом 2 типа и без него с помощью ингибитора SGLT2, такого как дапаглифлозин. Раскрытые в данном документе способы могут обеспечить снижение риска комбинированного исхода, включающего первый эпизод ухудшения сердечной недостаточности (госпитализация по причине сердечной недостаточности или срочный визит по причине сердечной недостаточности) или смерть по причинам, связанным с сердечно-сосудистым нарушением. Каждый из трех компонентов этого комбинированного исхода также может быть уменьшен, как и общее число госпитализаций по причине сердечной недостаточности и случаев смерти по причинам, связанным с сердечно-сосудистым нарушением. Ингибиторы SGLT2, такие как дапаглифлозин, могут также обеспечить снижение ухудшения симптомов сердечной недостаточности. Раскрытые в данном документе способы могут также обеспечить улучшение в отношении симптомов сердечной недостаточности, состояния здоровья и качества жизни.The present invention relates to methods of treating heart failure patients with reduced ejection fraction (HFrEF), with and without type 2 diabetes, with an SGLT2 inhibitor such as dapagliflozin. The methods disclosed herein can reduce the risk of a combined outcome including a first episode of worsening heart failure (hospitalization for heart failure or emergency visit for heart failure) or death from cardiovascular causes. Each of the three components of this combined outcome can also be reduced, as can the total number of hospitalizations for heart failure and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, may also reduce the worsening of heart failure symptoms. The methods disclosed herein can also provide improvements in heart failure symptoms, health status, and quality of life.

EA202090875A 2020-03-05 2020-03-09 METHODS FOR TREATMENT OF HEART FAILURE WITH REDUCED EMISSION FRACTION WITH DAPAGLIFLOSIN EA202090875A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985407P 2020-03-05 2020-03-05
PCT/EP2020/056211 WO2021037400A1 (en) 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Publications (1)

Publication Number Publication Date
EA202090875A1 true EA202090875A1 (en) 2021-03-31

Family

ID=75262233

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090875A EA202090875A1 (en) 2020-03-05 2020-03-09 METHODS FOR TREATMENT OF HEART FAILURE WITH REDUCED EMISSION FRACTION WITH DAPAGLIFLOSIN

Country Status (1)

Country Link
EA (1) EA202090875A1 (en)

Similar Documents

Publication Publication Date Title
MX2022008018A (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin.
Del Rio et al. Carotid body ablation abrogates hypertension and autonomic alterations induced by intermittent hypoxia in rats
Olsson et al. Acute kidney injury following coronary artery bypass surgery and long-term risk of heart failure
Bowen et al. Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle
La Rovere et al. Exercise-induced increase in baroreflex sensitivity predicts improved prognosis after myocardial infarction
Minamishima et al. Hydrogen sulfide improves survival after cardiac arrest and cardiopulmonary resuscitation via a nitric oxide synthase 3–dependent mechanism in mice
Piepoli et al. Skeletal muscle training in chronic heart failure
Kirkman et al. Exercise intolerance in kidney diseases: physiological contributors and therapeutic strategies
Czibik et al. Dysregulated phenylalanine catabolism plays a key role in the trajectory of cardiac aging
Na et al. Cervical ganglion block attenuates the progression of pulmonary hypertension via nitric oxide and arginase pathways
Rocca et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure Ermanno Eleuteri1, Francesca Magno1, 2, Isabella Gnemmi1, Marco Carbone1, 2, Marilena Colombo1, Giampiero La
Powers Exercise: Teaching myocytes new tricks
Angeloni et al. β-Blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting
Chung et al. Physiological serum bilirubin concentrations are inversely associated with the prevalence of cardiovascular autonomic neuropathy in patients with Type 2 diabetes
Givertz et al. Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study
Yang et al. Effect of diallyl trisulfide on ischemic tissue injury and revascularization in a diabetic mouse model
Salheen et al. The dipeptidyl peptidase-4 inhibitor linagliptin preserves endothelial function in mesenteric arteries from type 1 diabetic rats without decreasing plasma glucose
Westphal et al. The effect of brain death protocol duration on potential donor losses due to cardiac arrest
Shaheen et al. Cardiovascular and cerebrovascular comorbidities in hemodialysis patients from the Gulf Cooperation Council countries enrolled in the dialysis outcome and practice pattern study phase 5 (2012–2015)
Takano et al. Influence of atrial fibrillation on oxygen uptake and exercise tolerance in cardiovascular patients; close association with heart rate response
EA202090875A1 (en) METHODS FOR TREATMENT OF HEART FAILURE WITH REDUCED EMISSION FRACTION WITH DAPAGLIFLOSIN
Paula et al. Exercise training restores the myogenic response in skeletal muscle resistance arteries and corrects peripheral edema in rats with heart failure
De Reuck et al. Chronic obstructive pulmonary disease as a risk factor for stroke‐related seizures
Van Iterson et al. Therapeutic targets for the multi-system pathophysiology of heart failure: exercise training
Dubský et al. Impact of severe diabetic kidney disease on the clinical outcome of autologous cell therapy in people with diabetes and critical limb ischaemia